Ropinirole is used alone or with other medicines to treat Parkinson's disease. Ropinirole tablets are also used to treat a condition called Restless Legs Syndrome (RLS). RLS is a neurologic disorder that affects sensation and movement in the legs and caus + some more technical info. Ropinirole is a non-ergoline dopamine D2 and D3 receptor agonist with preferential activity at D3 sites, formulated as the hydrochloride salt for oral dosing; it stimulates postsynaptic dopamine receptors in the striatum to reduce motor symptoms in Parkinsonian syndromes and to modulate sensory-motor pathways in RLS. After oral administration ropinirole is rapidly absorbed with Tmax typically 1 to 2 hours, oral bioavailability is influenced by first-pass hepatic metabolism primarily via CYP1A2, and the elimination half-life in adults is around 6 hours under steady state conditions. Pharmacokinetic properties, dose titration recommendations, and interaction potential with CYP1A2 inhibitors or inducers should be considered in clinical use.
Parent: Ropinirole
Parent: Ropinirole
Parent: Ropinirole
Parent: Ropinirole
Parent: Ropinirole Hydrochloride / Ropinirole
Parent: Ropinirole
Parent: Ropinirole
Parent: Ropinirole
Typical quality control specifications for ropinirole active pharmaceutical ingredient require high purity and low levels of related substances; a representative specification would include assay of active substance greater than or equal to 98.0 percent, any single unspecified impurity not exceeding 0.2 percent, and total impurities not exceeding 1.0 percent, with tighter limits of 0.05 to 0.2 percent applied to specified related compounds as dictated by regulatory guidance. Known related substances and degradation products include ropinirole N-oxide, N-despropyl ropinirole, hydroxylated positional isomers, and trace polar degradants formed under oxidative or hydrolytic stress; these species are monitored by validated HPLC or LC-MS methods and controlled through appropriate synthetic route selection, purification, and stability-indicating packaging.
Ropinirole is used to treat motor symptoms of Parkinson’s disease either as monotherapy in early disease or as adjunct therapy with levodopa in advanced disease. Ropinirole tablets are also used to treat Restless Legs Syndrome, a neurologic disorder that affects sensation and movement in the legs.
Ropinirole acts as an agonist at dopamine D2 and D3 receptors, producing dopaminergic stimulation in the striatum and related pathways. This receptor activation alleviates Parkinsonian motor deficits and modulates sensory-motor signaling implicated in RLS. The compound is not a dopamine precursor; it directly stimulates postsynaptic dopamine receptors.
Adverse effects can include nausea, dizziness, somnolence, orthostatic hypotension, hallucinations, and peripheral edema. Impulse control disorders such as compulsive gambling, eating, or hypersexuality have been reported. Sudden onset of sleep and worsening of psychiatric symptoms are possible. Risk-benefit assessment and patient counseling are important before and during treatment.
No. Ropinirole is not an antipsychotic. It is a dopamine receptor agonist used primarily for Parkinson’s disease and Restless Legs Syndrome, whereas most antipsychotics are dopamine receptor antagonists used to treat psychotic disorders.
